Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1643-1645

  Matsuzaki, Juntaro ^a   Suzuki, Hidekazu ^a   Nishizawa, Toshihiro ^a,b   Hirata, Kenro ^a   Tsugawa, Hitoshi ^a   Saito, Yoshimasa ^c   Okada, Sawako ^a   Fukuhara, Seiichiro ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; SITAFLOXACIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; FEMALE; FIRST AID; GENE MUTATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTENTION TO TREAT ANALYSIS; JAPANESE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BIOMARKERS, PHARMACOLOGICAL; CLARITHROMYCIN; DNA GYRASE; FEMALE; FLUOROQUINOLONES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; TREATMENT FAILURE;

EID: 84863394554     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05941-11     Document Type: Article

References (9)

1. Gisbert JP, Morena F. 2006. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment. Pharmacol. Ther. 23:35-44. (Pubitemid 43381164)
2. Lee JW, et al. 2011. Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea. Helicobacter 16:301-310.
3. Liou JM, et al. 2011. Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. Antimicrob. Agents Chemother. 55:1123-1129.
4. Miyachi H, et al. 2006. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter 11:243-249. (Pubitemid 44051350)
5. Nishizawa T, et al. 2006. Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan. Antimicrob. Agent Chemother. 50:1538-1540.
6. Nishizawa T, et al. 2008. Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication. J. Gastroenterol. Hepatol. 23(Suppl 2):S167-S170.
7. Perna F, et al. 2007. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig. Liver Dis. 39:1001-1005. (Pubitemid 350018698)
8. Suzuki H, Nishizawa T, Muraoka H, Hibi T. 2009. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. Antimicrob. Agent Chemother. 53:1720-1721.
9. Yamade M, et al. 2011. Resistance of Helicobacter pylori to quinolones and clarithromycin assessed by genetic testing in Japan. J. Gastroenterol. Hepatol. 26:1457-1461.